Clinical Trial Update: Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing G17DT immunogen plus gemcitabine versus gemcitabine alone in advanced pancreatic cancer assessing safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• G17DT immunogen
• Gemzar (gemcitabine)

Snippet

Sponsor: Cancer Advances Inc. | Conditions: Pancreatic Cancer | Phase 3 | Status: COMPLETED